Community Pharmacy Wales and Welsh Govt Agreement on CPCF

Community Pharmacy Wales and the Welsh Government reached an agreement on Thursday, December 16, allowing all pharmacies to provide contraceptives, treatment for common minor ailments and access to repeat medication in an emergency.

The expansion of the Community Clinical Pharmacy service will be supported by increased funding of £20m per year by April 2024 from the current level of £11.4m.

The two organizations have negotiated the terms of the agreement, which also includes plans to roll out a pharmaceutical prescription service across Wales, enabling trained pharmacists to treat a wide range of conditions that currently require visits to a general practitioner.

The deal will allow patients to access NHS services closer to home, which would free up GP services and other NHS services for patients with more complex needs.

Eluned Morgan MS, Minister for Health and Social Care, said: “I welcome the positive approach to negotiations taken by Community Pharmacy Wales, embracing our ambition for a reinvented community pharmacy service, which is an integral part of a strong primary care landscape.”

“The new provisions recognize and reward pharmacies, which understand, share and fulfill our longer-term ambition to provide efficient, high-quality and sustainable healthcare.”

Mark Lyonette, CEO, National Association of Pharmacists

Welcoming the agreement, Mark Lyonette, chief executive of the National Pharmacy Association (NPA), said it shows “the Welsh Government’s willingness to support its ambitions to expand pharmaceutical services with financial investment.

“NPA members across Wales provide invaluable access to care, professional support and are trusted. Collaborative leadership in Wales has been a spur to many positive outcomes that benefit patients and we look forward to working with our members to ensure they continue to provide excellent care to the people of Wales.

If you would like to share your stories and/or experiences with us, please email [email protected]

Comments are closed.